Specific beneficial gut bacteria

Specific beneficial gut bacteria, collectively known as the commensal microbiota, are integral components of the human gastrointestinal tract that maintain host health through metabolic and immunological contributions (NIH: PMC3983973). These microorganisms facilitate the digestion of complex carbohydrates into short-chain fatty acids (SCFAs), such as butyrate, which serve as energy sources for colonocytes and exert anti-inflammatory effects (Nature: s41579-020-0433-9). They also provide a competitive barrier against pathogenic colonization and are essential for the proper development of the host's mucosal immune system. In clinical contexts, the depletion or imbalance of these bacteria—known as dysbiosis—is a hallmark of conditions like Clostridioides difficile infection (CDI), inflammatory bowel disease (IBD), and various metabolic syndromes (PubMed: 32398771). Therapeutic interventions, including Live Biotherapeutic Products (LBPs) and fecal microbiota transplantation (FMT), aim to restore these populations to achieve therapeutic outcomes (FDA: 82121). Consequently, these bacteria are increasingly viewed as modifiable therapeutic targets for a wide range of systemic and localized diseases.

Other names

Commensal gut microbiotaProbioticsBeneficial microbesLive Biotherapeutic Products (LBPs)Gut floraHealthy gut microbiome

Restoration of microbial diversity, competitive exclusion of pathogenic species, production of antimicrobial peptides (bacteriocins), synthesis of short-chain fatty acids (SCFAs) to maintain epithelial integrity, and modulation of host immune signaling through T-regulatory cell induction.